

CURRICULUM VITAE

**MARY ALICE MALUCCIO, MD, MPH, FACS**

**Current Title:** Professor of Surgery (with Tenure)

**Business Address:** LSU Health – New Orleans School of Medicine Department of Surgery Section of Surgical Oncology 2021 Perdido Street

New Orleans, LA 70112

## Business Telephone

**and Fax:** (504) 503-5426 p; (504) 383-0055 (f)

**Business email Address:** [mmaluc@lsuhsc.edu](mailto:mmaluc@lsuhsc.edu)

## Education

**Undergraduate:** University of California at Berkeley

BA French 12/1986

**Graduate/Medical:** Combined MD/MPH - Columbia University College

of Physicians and Surgeons and Columbia Mailman School of Public Health

May 1994

**Internship:** New York Presbyterian Hospital

General Surgery Residency 1994-1995

**Residency:** New York Presbyterian Hospital General Surgery Residency 1995 - 2002

## Post-Doctoral

**Fellowships:** National Research Service Award (T32)

NIH Post-Doctoral Fellowship – Surgical Oncology 1997 - 1998

National Research Service Award (F32) NIH - Surgical Oncology

1998 - 2000

**Clinical Fellowships:** Memorial Sloan Kettering Cancer Center

Surgical Oncology 2002 - 2004

**Other:**

Leadership in Academic Medicine Program 2004-2006

AACR Clinical Methods Course 2005

ASCO Clinical Cancer Research Program 2007

Scripts Institute Grant Application Writers Workshop 2009 American College of Surgeons Outcomes Research Course 2010

Society of University Surgeons Mid-Career Development Course 2010

Society of University Surgeons Leadership Development Course 2016 Leadership in Academic Medicine II 2016

Kellogg School of Business Executive Education Program 2016

Next Generation Leadership Course 2017

Chairman’s Leadership Development Program 2017-2019

IU Kelley School of Business -Business and Medicine Course 2018-2019

LSU Media in Medicine course 2022

Harvard Business School: Exercising Leadership: Foundational Principles 2023

## Certification:

American Board of Surgery, General Surgery, #048495

October 27, 2003 - December 31, 2024

Certification in Surgical Oncology 5/2004

## Licensure:

Medical Licensing Board of Indiana, #01059879A, 10/19/2004 (active) Louisiana State Board of Medical Examiners, #311861, 2/18/2019 (active) Oklahoma Board of Medical Licensure, #39087, 1/19/2022 – 1/1/2023 (active) Mississippi State Board of Medical Licensure, #29801 12/2021 (active) Alabama Medical Licensure Commission, #MD.43768, 1/10/2022 (active) Georgia Composite Medical Board, #90964, 1/11/2022 (active)

Texas Medical Board (pending)

## Credentialed hospitals:

2003 - 2019 Indiana University Medical Center, Eskenazi Health Medical Center, Richard L. Roudebush Veterans' Administration Medical Center. Indianapolis

2019 – 1/2023, Ochsner Kenner Medical Center, Louisiana 7/2022-present LCMC East Jefferson Hospital, Louisiana

## Academic, Professional, and Research Appointments Academic Appointments:

Indiana University, School of Medicine, Department of Surgery, Assistant Professor-tenure track, 9/2004 – 6/2009

Indiana University, School of Medicine, Department of Surgery, Associate Professor with tenure, 7/2010 – 6/2016

Indiana University School of Medicine, Department of Surgery, Professor of Surgery with tenure, 7/2017 – 6/2019

Louisiana State University School of Medicine, Department of Surgery, Professor of Surgery with Tenure, 07-01-2019 – present

Louisiana State University Department of Surgery, Medical Director, New Orleans Louisiana Neuroendocrine Tumor Program 7/2019 – present

Louisiana State University Department of Surgery, Chief of the Division of Surgical Oncology 7/2020 – present

Medical Director, LCMC Rare Cancer Program 7/2022 – present

## Professional Appointments:

Director IU Simon Cancer Center Hepatobiliary Program 2008 – 2019

Medical Director, IUH Systemwide Liver Oncology Program 2010 – 2019

Director – Transplant Immunology and Biorepository Lab 2010 - 2019

Director- Multidisciplinary Liver Oncology Clinic 2016 – 2019

Medical Director, IU Health CLIA/CAP lab 2016 – 2019

Medical Director, NOLANETS 7/2019-present Medical Director, LCMC Rare Cancer Program 7/2022-present

## Departmental/Institutional Committees:

Cancer Center Executive Committee Cancer Advisory Board 2011-2020

American Board of Surgery- examiner 2012 – present Surgical Dept Representative IUH Human Resources Committee 2016 - 2019

Louisiana State University Department of Surgery

Chairman, Tenure and Promotion Committee 7/2020 – 3/2023 Department of Surgery Residency Review Committee 2020 – present Member – Clinical Science Grant Review 2020 - present

## Membership in Professional Organizations:

Society of Surgical Oncology 2002 (active)

American College of Surgeons 2004 (active) American Hepatopancreaticobiliary Association (AHPBA) 2005-2019 (inactive) Association of Academic Surgery (AAS) 2005-2019 (inactive)

American Association of Women Surgeons 2009 (active) Society of University Surgeons (SUS) Elected 2010 (active) Fellow of the ACS Elected 2010(active) American Association of Cancer Research (AACR) 2010 (active)

American Society of Clinical Oncology (ASCO) 2010-2019 (active) American Board of Surgery Examiners 2011 (active) National Association of Neuroendocrine Tumor Specialists 2012 (active) Central Surgical Association Elected 2018 (inactive)

MASELA 2022 – present

CAGLA Scientific Advisory Board 1/2023 - present

## Awards and Honors:

|  |  |  |
| --- | --- | --- |
| ***TEACHING***  IU Trustee Teaching Award Indiana University | | 2009 |
| Resident Surgical Educator of the Year | | 2019 |
| ***RESEARCH***  Individual National Research Service Award (F32) – NIH | | 1997 – 1998 |
| Top Abstract Award -American Society of Transplant Physicians | | 2000 |
| Young Investigator Award - American Society of Transplantation | | 2000 |
| Resident Research Award - Surgical Infection Society | | 2001 |
| Faculty Research Award -American Surgical Assn | | 2005 |
| James Ewing Award for Basic Research-Society of Surgical | Oncology 2006 | |
| Young Investigator Award in Gi Oncology, IUSCC | 2006 | |
| Walther Institute Faculty Development Award | 2012 | |
| ***SERVICE***  Top Doctor-Indianapolis Monthly | 2013 – 2019 | |
| Best Doctor in America recognition | 2013 – 2020 | |
| Top Doctor in Surgery Castle Connolly | 2016 – 2019 | |
| Top Surgical Oncologist- Health Tap | 2016 | |
| Neuroendocrine Cancer Awareness Network Above and Beyond Award | 2023 | |
| ***OTHER***  Alpha Omega Alpha Columbia University | 1994 | |
| Robert Bertsch Prize in Surgery Columbia University | 1994 | |

Emily Davis and Joseph Kornfield Foundation

Fellowship in Human Rights and Medicine Columbia University 1994

# TEACHING EXPERIENCE AND RESPONSIBILITIES

## Course/Clerkship/Residency or Fellowship/CME Directorships:

Summer Research Program for undergraduate and medical students – Our laboratory participated in the Indiana University Summer Research Program targeting undergraduate students and medical students interested in spending time in a research laboratory. A full list of student participants is available on request. **1-2 students/summer 2010-2019**

*American College of Surgeons Panel Member – Neuroendocrine 2014* One of 4 panelists and the only surgical representative evaluating diagnostic and treatment paradigms for neuroendocrine cancers, including consideration of transplant. **2014**

*IU Surgical Skills Lab* – Human cadaver and porcine skills covering hepatobiliary anatomy and surgical procedures. **Faculty 6 times per year, 2008-2018**

## Curriculum Development/Implementation:

Via Oncology Clinical Pathways Clinical Faculty (Active) I developed the evidence-based clinical pathways for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma, including indications for consideration of liver transplant in the setting of cancer. **2014-2019**

## Creation of Enduring Teaching Materials:

### Self- Evaluation and Self-Assessment Program in Oncology (SESAP) 2005- 2014

As a member of the education committee of the American Board of Surgery, we developed a self-assessment tool covering questions in oncology for residents preparing for the written board of surgery examination. **2 meetings/year**

### Surgical Oncology Didactic Curriculum 2005 - 2019

This Curriculum included the key principles for medical and surgical management of the common cancers seen and managed by surgeons and surgical subspecialists. The target learners were surgical residents and medical students.

### Teaching Interns to Teach Didactic Curriculum 2006-2018

This curriculum was developed to address teaching expectations for the residents and targeted the entering intern class over the first 3 months of the resident rotation schedule. It included topics on personal responsibility, accurate sign out, time management, delegation, and role responsibilities for each resident level.

### Problem Based Learning Modules 2006-2018

This curriculum included medical topics managed by surgeons and surgical subspecialists but targeting the medical student learner during their surgical and surgical subspecialty rotation. Faculty 3 times per year for 6 week blocks.

### Student Summer Research Program 2010-2019

This curriculum included basic skills in scientific method, research project development, data analysis, and manuscript preparation for undergraduate and medical students

### Cancer Control Journal - Liver Oncology Expert Panelist – 2013

One of four national experts and the only surgeon to sit on this panel. The Cancer Control Journal is a major contributor to evidence-based treatment paradigms.

## Formal Course Responsibilities

***Summer Surgical Oncology Didactic Program* 2005 – 2018**

This 9-session course took place every summer. The target learner was residents and medical students. The objectives of the course included a progressive understanding of the diagnosis and surgical management of cancer

### Didactic Curriculum - Liver Anatomy 2005-2018

As Medical Director of the hepatobiliary service of the cancer center, I developed a curriculum on liver anatomy for the medical and surgical resident staff. This involved the accurate interpretation of ultrasound and cross-sectional imaging, including assessment of surgical intervention. Faculty 3 times/year.

### America Board of Surgery Board Review 2004-2011

This curriculum targeted 3rd to 5th year residents preparing for the written and oral surgical boards. My responsibility focused on topics in surgical oncology, benign and malignant hepatic and pancreatic disease, sarcoma, melanoma, thyroid and parathyroid, MEN, familial cancer syndromes, and strategies for handling oral board questions. Faculty 2 times per year until I entered the pool of examiners for the oral board exam through the ABS.

## Departmental/Interdisciplinary Teaching Conferences

Indiana University Liver Oncology Tumor Board Director and Faculty **2005-6/2019** This CME activity met weekly and was attended by all staff members of the liver oncology program and including fellows and residents rotating on surgical, medical, and radiology rotations.

IU GI Oncology Tumor Board Faculty **2005-6/2019**

This CME activity met weekly and was open to all faculty members treating patients with non-liver GI cancers, including colorectal, pancreatic, stomach, GIST, and lymphoproliferative disorders involving the GI tract.

IU Simon Cancer Center Interdisciplinary conference faculty **2007-6/2019**

This CME activity met monthly and was attended by cancer physicians and research staff and included invited lectureships, disease specific working group

updates and a review of multidisciplinary clinic protocols, research projects, and clinical trial accrual.

LSUHSC Neuroendocrine Program Clinical Conference Director and Faculty

## 7/2019-2021

This CME activity met weekly and was attended by all members of the NET working group and open to all faculty members treating patients with neuroendocrine tumors of the head and neck, lung, and GI tract.

LSUHSC Grand Rounds Faculty of the Month. **April 2021, September 2022** Generate, organize, recruit speakers and deliver faculty grand round lectures pertaining to surgical oncology education.

LSUHSC Cohn’s Conference Moderator. **3 times per year 2019-present**

Moderator medical student presentations as part of the didactic program of the surgical clerkship for MS3 students

|  |  |
| --- | --- |
| **Teaching Awards:** |  |
| IU Trustee Teaching Award Indiana University | 2009 |
| Resident Surgical Educator of the Year | 2019 |
| **Undergraduate, Medical, or Graduate Students Trained:** |  |

Angela Qualey Medical student advisor, IU 2007

Andrew Prather Medical student advisor, IU 2007

Selyne Samuels Medical student research preceptor, IU 2013

Tyrone Davis Medical student research advisor, IU 2013

Angela Mah Medical student research advisor, IU 2014

Taylor Coleman Medical student research advisor, IU 2015

Eric He. Undergraduate Research Preceptor, IU 2016

Samuel Leeds Undergraduate Research Preceptor, IU 2016 – 2019

Sherene Lattimore Medical student research advisor, IU 2017 – 2019

Shaniqua Ries Medical student research advisor, IU 2017 – 2019

Taylor Munsch Medical student research advisor, IU 2017 - 2019

Campbell Elliott Post Graduate Research Preceptor IU 2018 – 2019

Austin Sgroi Undergraduate Research Preceptor, IU 2018 – 2019

Caroline Vegas Undergraduate Research Preceptor, IU 2018 – 2019

Baily Gentile Medical Student Tulane 2019 – 2023

Jackline Mehrez Undergraduate Research Preceptor, LSU 2019 – 2020

Kenneth Avanzino Postgraduate Research Preceptor, LSU 2020 – 2021

Michael Maurer Postgraduate Research Preceptor, LSU 2021 – 2022

Alexis Vega Medical Student Clinical Preceptor, LSU 2022-2023

Joseph Mason Medical Student Preceptor, LSU 2023

## Thesis and Dissertation Committees:

Amanda Cooper – MS Advisory Committee. Indiana University

**Post-Doctoral or Post-Residency Fellows Trained:**

|  |  |  |
| --- | --- | --- |
| Kari Burns MD | Faculty Advisor | 2005 – 2008 |
| Hari Kumar MD | Faculty Advisor | 2005 – 2008 |
| Rachell Scott MD., | Faculty Research Advisor | 2005 – 2010 |
| Colleen Murphy MD | Faculty Research Advisor | 2006 – 2009 |
| Dawn Larson MD | Faculty Advisor | 2006 – 2009 |
| Ray Chihara MD | Faculty Advisor | 2007 – 2014 |
| Daniel Weber MD | Faculty Advisor | 2011 – 2016 |
| Joanna Hunter MD | Faculty Advisor | 2011 – 2016 |
| Andrew Lutz MD | Faculty Advisor | 2014 – 2015 |
| Shilpa Murthy MD | Senior resident clinical preceptor | 2016 |
| Adam Gracon MD | Senior resident clinical preceptor | 2016 |
| Carlo Rosati MD | Senior resident clinical preceptor | 2016 |
| Lucas McDuffie MD | Senior resident clinical preceptor | 2017 |
| Steven Mong MD | Senior resident clinical preceptor | 2017 |
| Matthew Field MD | Senior resident clinical preceptor | 2017 |
| Tejas Nkunmbah MD. | Research Preceptor | 2017 – 2019 |
| James Butler MD | Senior resident clinical preceptor | 2018 |
| Jace Landry, MD | Senior resident clinical preceptor, LSU | 2021 |

# RESEARCH AND SCHOLARSHIP

## Grants and Contracts Funded

### Current Research Grants:

1. **LA-CATS** The role of CD 73 in gastrointestinal neuroendocrine cancers. Advisor $ 50,000

### Previous Funded Grants:

1. **T32** The Impact of Immunosuppression on solid organ tumor biology. NIH Research Fellow 7/1997-6/1998 $75,000
2. **NIH F32** - CA75732: Optimizing Immunotherapy of Renal Cell Carcinoma NIH Research Fellow 7/1998-6/2000 $150,000
3. **Biomedical Research Grant**: Lipid Mediators in hepatitis C associated HCC IUPUI. Principal investigator $100,000
4. **K22 - CA111393**: The Renin-angiotensin system in hepatitis and hepatoma NIH Principal Investigator. 10/2004-9/2007 $475,000
5. **James Ewing Society Research Award**. The Hepatic Stellate Cell in Human Hepatocellular Carcinoma. Society of Surgical Oncology. Principal Investigator 2005-2007 $100,000
6. **GI Oncology Grant**. NF-kB as a mechanism behind hepatocellular cancer growth. Principal Investigator 2008 $50,000
7. **Walther Cancer Center Research Award**. Early Biomarkers of Cancer risk in Patients with Hepatitis. Principal Investigator 2010 $100,000
8. **Indiana University Research Support Funds Grant**. Targeting aberrant lipid signaling to inhibit hepatocellular carcinoma Principal Investigator. Principal Investigator 2010 $30,000
9. **Showalter Grant**. Early Predictors of response of hepatocellular carcinoma using novel MRI techniques Showalter Foundation. Co-investigator 2011 $100,000
10. **Clarian Values Grant.** The absolute Impact of transplantation on liver cancer survival. Principal Investigator 2011 $100,000
11. **Liver Oncology Research Grant**. Biomarkers and chemoprevention in liver cancer. Principal Investigator $50,000
12. ***RSFG*** Targeting aberrant lipid signaling to inhibit hepatocellular carcinoma. Principal Investigator $50,000
13. **NIH R21 CA133770**: Metabolomic based identification of hepatocellular cancer biomarkers. Co-Principal Investigator 2012-2015 $325,000
14. **IU Health Liver Oncology Translational Research Program** IU Health. Principal Investigator. This funding included a non-compete renewal and negotiated on the value of the lab-based infrastructure to support on-campus, off-campus in-state, and national collaborations aimed at improving outcomes for patients with primary and secondary liver cancers. The evolution of this project put us in a position to be a central core lab for MALDI mass spectroscopy nationally. 2013-2019

$1,600,000

1. **Indiana University Biomedical Research Grant**. Biomarkers of hepatocellular Carcinoma. Principal Investigator 2016 $100,000
2. **Indiana University CTSI (NIH**) MRS imaging for Hepatocellular carcinoma. Principal Investigator 2016 $50,000
3. **Indiana Drug Discover Alliance**. Chemoprevention for hepatocellular carcinoma. Principal Investigator 2017 $50,000
4. **Indiana Center for bio-innovation**. Novel DDAH molecule to prevent hepatic ischemia reperfusion. Principal Investigator 2018-2020 $100,000
5. **Ochsner 2020 Excellence Award Research Fund**: Use of Immunonutrition to Decrease Morbidity and Increase Quality of Life in Patients with Neuroendocrine Tumors. Principal Investigator 2021-2022. $20,000

### Current Industry Sponsored Clinical Trials:

1. ***Alphamedix.*** Phase II trial of Dotamtate 212Pb in patients with metastatic neuroendocrine malignancies. Principal Investigator 2022. Estimated total budget with accrual goal N=8 Estimated total budget $500,000 plus guaranteed payment on clinic imaging for 2 years.
2. ***Camarus***: Randomized, Multicenter, Open Label, Active Controlled, Phase III Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot versus LAR or Lanreotide ATG in Patients with Gastroenteropancreatic Neuroendocrine Tumours. Principal Investigator 2022. Estimated total budget with accrual goal N=30 $1,450,000
3. ***Curium IIS:*** Intraoperative Molecular Imaging using Cu64-DOTATATE Principal Investigator 2022 Estimated value with accrual goal 30 $240,000

### Industry Sponsored Clinical Trials in contract:

1. **Crinetics:** Phase 2 Randomized parallel group study to evaluate the safety, pharmacokinetics, and dose response of Paltusotine treatment in subject with carcinoid syndrome. Estimated total budget with accrual goal N=10 $311,000
2. **RayzeBio**: Phase 1b/3 global, randomized controlled, open-label trial comparing treatment comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing, well differentiated gastro-entero-pancreatic neuroendocrine tumors (GEP-NETS) that have progressed following prior treatment with 177Lu-DOTATATE or 177Lu- DOTATOC. Estimated total budget with accrual goal 12 TBD

### Awarded Clinical Trials we declined due to inter-institutional barriers:

1. ***COMPOSE:*** A Prospective, randomized Controlled, Open-label, Multi-centre study to evaluate the efficacy, safety, and Patient Reported Outcomes of PRRT with Lu177-Edotreotide 2021 Principal Investigator. Estimated total budget with accrual goal N= 8, $800,000
2. ***Salus:*** An International, Non-Interventional, Post Authorization Long-Term Safety Study of Lutathera in Patients with Unresectable Metastatic Well-Differentiated, SSR positive, Gastroenteropancreatic Neuroendocrine Tumors Principal Investigator 2021 Estimated total budget with accrual goa N=75 $750,000

### Completed Clinical Trials:

* 1. Investigator Initiated: Phase I trial of Stereotactic Body Radiation Therapy for primary hepatocellular carcinoma. 2008 Co-Principal Investigator $85,000
  2. Investigator Initiated: Phase II trial of Stereotactic body Radiation Therapy for hepatic oligometastases. 2012-2013 Co-Principal Investigator $125,000
  3. Investigator Initiated: Phase II trial of Stereotactic Body Radiation Therapy for primary hepatocellular carcinoma 2012-2013 Co-Principal Investigator $125,000

### Investigational New Devices (IND):

1. 2013 - IND Utilization of Ga68 imaging in patients with neuroendocrine malignancies. Co-principal investigator
2. 2014 - IND C11-Acetate Imaging in hepatocellular carcinoma. Co-Principal Investigator

### Pending grant applications:

### Neuroendocrine Tumor Research Fund (NETRF) Principal Investigator $100,000

### Tareting DNA repair mechanisms in neuroendocrine tumors.

Neuroendocrine Tumor Research Fund (NETRF) Pilot Project Award. $100,000 Monitoring and targeting CD73 for gastrointestinal neuroendocrine neoplasms. Principal Investigator $100,000

NIH NCATS PAR-22-101 (R21) Clinical Trial Preparations for Rare Cancers. 2022 Principal Investigator $275,000

American Cancer Society Discover Award. Disparities in Rare Cancers. How Rare Cancer diagnoses impact outcomes in the Southern US. 2022 Principal Investigator $100,000

NIH NCATS RFA-TR-22-030 (R03). Quantification and Elucidation of Understudied Proteins in Rare Neuroendocrine Tumors. 2022 Principal Investigator $100,000

### Recent non-funded applications:

1. Department of Defense Discovery Award W81XWH-20-PRMRP-DA. 2020 Utilization of metabolomics to optimize nutrition in patients with liver disease. Principal Investigator
2. NIH RFA-TR-20-001 R01 2020 Translational Research Access Disparities for Rare Cancers. Principal Investigator
3. Louisiana Clinical and Translational Science Center (NIH).2020 Community partnership to study clinical trial access disparities for rare cancers. Principal Investigator
4. 1 R21 CA256868-01A1.2020 Social Determinants of Disparities in Hepatocellular Carcinoma. Multiple Principal Investigator
5. LSU Clinical Research Grant. 2020 [31] NMR profiles and hepatocellular carcinoma Mary Maluccio MPI, Robert Cook (Baton Rouge) MPI, Nicholas Skill MPI
6. Center for Clinical and Translational Interdisciplinary Network Pilot Program (NIH/NCATS) 2021 Geographical and Socioeconomic Disparities Linked to Rare Cancers. Maluccio, Mary MPI, Wahmann Mary MPI
7. LSU Clinical Research Grant 2021 Hepatic CYP2W1 in liver disease continuum to liver cancer. Mary Maluccio MPI, Martin Ronis MPI, Nicholas Skill MPI.
8. Neuroendocrine Research Foundation 2021 Defining metabolic signatures to personalize NET treatment. Mary Maluccio MPI, and Nicholas Skill MPI
9. LA CaTS 2021 Metabolic Signatures as a surrogate of response to NET treatment Nicholas Skill MPI, Robert Ramirez MPI, and Mary Maluccio MPI
10. Ochsner Excellence Fund 2021 Intraoperative molecular imaging with 64Cu- DOTATATE. Maluccio, Mary PI

## Journal Publications Refereed:

1. Weyant MJ, **Maluccio MA**, Bertagnolli MM, Daly JM. Choledochal cysts in adults – A report of two cases and review of the literature. American Journal of Gastroenterology. 1998;93(12):2580
2. Hojo M, Morimoto T, **Maluccio M**, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530-4.
3. **Maluccio M**, Rao J, Sharma VK, Lagman M, Suthanthiran M. A novel immunoregulatory role for anti-CD3 mAbs: Dendritic cells, pulsed with tumor cells and armed with anti-CD3 mAbs, are highly effective in constraining tumor progression. Transplantation. 1999;67(7):S210-S.
4. Rao J, **Maluccio M**, Talmor M, Kapur S, Suthanthiran M, Kinkhabwala M. Dendritic cell conditioning with cyclosporine: Conversion from an immunizing to a tolerogenic phenotype. Transplantation. 1999;67(7):S210-S.
5. **Maluccio M**, Konijn G, Lagman M, Suthanthiran M. Angiotensin II receptor blockade: A novel strategy to prevent immunosuppressant associated cancer progression. Transplantation. 2000;69(8):S392-S..
6. **Maluccio MA**, Rao J, Sharma V, Lagman M, Suthanthiran M. Dendritic cells armed with anti-CD3 mAbs reduce pulmonary metastases, prolong survival, and engender antitumor effector cells demonstrable by adoptive transfer. Annals of Surgical Oncology. 2000;7(10):771-6.
7. Weyant MJ, Eachempati SR, **Maluccio MA**, Rivadeneira DE, Grobmyer SR, Hydo LJ, Barie PS. Interpretation of computed tomography does not correlate with laboratory or pathologic findings in surgically confirmed acute appendicitis. Surgery. 2000;128(2):145-52.
8. **Maluccio M**, Sharma V, Lagman M, Konijn G, Suthanthiran M. Angiotensin II receptor blockade: A novel strategy to prevent immunosuppressant-associated cancer progression. Transpl P. 2001;33(1-2):1820-1.
9. Covey AM, Brody LA, **Maluccio MA**, Getrajdman GI, Brown KT. Variant hepatic arterial anatomy revisited: Digital subtraction angiography performed in 600 patients. Radiology. 2002;224(2):542-7.
10. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation. 2002;73(10):1565-72
11. **Maluccio M**, Sharma V, Lagman M, Vyas S, Yang H, Li BG, Suthanthiran M. Tacrolimus enhances transforming growth factor-beta(1) expression and promotes tumor progression.Transplantation.2003;76(3):597-602.
12. **Maluccio M**, Covey AM, Gandhi R, Gonen M, Getrajdman GI, Brody LA, Fong YM, Jarnagin W, D'Angelica M, Blumgart L, DeMatteo R, Brown KT. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. Journal of Vascular and Interventional Radiology. 2005;16(7):955-61.
13. Moore KH, **Maluccio M**, Jaques D. Is surgical oncology training meeting expectations? Annals of Surgical Oncology. 2005;12(2):S37-S..
14. Covey AM, **Maluccio MA**, Brody LA, Sofocleous CT, Getrajdman GI, Brown KT. Re: Society of interventional radiology position statement on chemoembolization of hepatic malignancies. Journal of Vascular and Interventional Radiology. 2006;17(7):1209-.
15. **Covey AM**, Maluccio MA, Schubert J, BenPorat L, Brody LA, Sofocleous CT, Getrajdman GI, Fong Y, Brown KT. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer. 2006;106(10):2181-9.
16. **Maluccio MA**, Covey AM, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, DeMatteo R, Brown KT. Treatment of metastatic sarcoma to the liver with bland embolization. Cancer. 2006;107(7):1617-23. doi: 10.1002/cncr.22191.
17. Al-Azzawi HH, Nakeeb A, Saxena R, **Maluccio MA**, Pitt HA. Cholecystosteatosis: an explanation for increased cholecystectomy rates. Journal of Gastrointestinal Surgery. 2007;11(7):835-42.
18. Cooper A, Mangus RS, **Maluccio M**, Vianna R, Fridell JA, Tector AJ. Impact of extended criteria donor livers on survival of patients with hepatocellular carcinoma. Gastroenterology. 2007;132(4):A756-A..
19. Cooper A, Wu JM, and **Maluccio M**. Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer? Gastroenterology. 2007;132(4):A838-A.
20. Cooper AB, Mangus RS, **Maluccio M**, Fridell J, Vianna R, Tector AJ. Success of liver transplantation in patients with multifocal hepatocellular carcinoma. Am J Transplant. 2007;7:469-.
21. Cooper AB, Wu JM, Lu DB, and **Maluccio MA**. Is autotaxin (ENPP2) the link between Hepatitis C and hepatocellular cancer? Journal of Gastrointestinal Surgery. 2007;11(12):1628-34.
22. Cardenes H, Price T, Perkins S, **Maluccio M**, Kwo P, Breen T, Henderson M, Tudor K, DeLuca J, Johnstone P. Phase I trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Int J Radiat Oncol. 2008;72(1):S128-S9.
23. Cooper A and **Maluccio MA**. A decision analysis model of hepatectomy vs. radiofrequency ablation for hepatocellular carcinoma. Gastroenterology. 2008;134(4):A868-A.
24. **Maluccio MA**, Covey AM, Ben Porat L, Schubert J, Brody LA, Sofocleous CT, Getrajdman GI, Jarnagin W, DeMatteo R, Blumgart LH, Fong Y, Brown KT. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. Journal of Vascular and Interventional Radiology. 2008;19(6):862-9.
25. Mangus RS, **Maluccio M**, Kumar H, Fridell JA, Vianna RM, Jones DT, Tector AJ. Pre-Transplant Liver Directed Therapy for Hepatocellular Carcinoma Improves Post-Transplant Survival. Liver Transplant. 2008;14(7):S218-S. PubMed PMID: WOS:000264144700531.
26. Wu JM, Nakshatri H, and **Maluccio MA**. NUCLEAR FACTOR kappa B (NF-kappa B) INHIBITION INCREASES THE SENSITIVITY OF HEPATOCELLULAR CARCINOMA (HCC) TO RADIATION INDUCED CELL DEATH. Hepatology. 2008;48(4):1118a-a.
27. Gowda GA, Shanaiah N, Cooper A, **Maluccio M**, Raftery D. Visualization of Bile Homeostasis Using H-1-NMR Spectroscopy as a Route for Assessing Liver Cancer. Lipids. 2009;44(1):27-35. doi: 10.1007/s11745-008-3254-6..
28. Gowda GAN, Shanaiah N, Cooper A, **Maluccio M**, Raftery D. Bile Acids Conjugation in Human Bile Is Not Random: New Insights from H-1-NMR Spectroscopy at 800 MHz. Lipids. 2009;44(6):527-35. doi: 10.1007/s11745-009- 3296-4.
29. Price TR, Perkins SM, Sandrasegaran K, Henderson MA, **Maluccio MA**, Zook JE, Tector AJ, Vianna RM, Johnstone PAS, Cardenes HR. Evaluation of Response after Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol. 2009;75(3):S677-S8
30. Theodorakis NG, Wang YN, Wu JM, **Maluccio MA**, Sitzmann JV, Skill NJ. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model. Am J Physiol-Gastr L. 2009;297(4):G792-G9.
31. Thornton RH, Covey A, Petre EN, Riedel ER, **Maluccio MA**, Sofocleous CT, Brody LA, Getrajdman GI, D'Angelica M, Fong Y, Brown KT. A Comparison of Outcomes From Treating Hepatocellular Carcinoma by Hepatic Artery Embolization in Patients Younger or Older Than 70 Years. Cancer. 2009;115(21):5000-6.
32. Wu JM, **Maluccio M**. Altered expression pattern of phospholipid metabolism genes in HCV-related hepatocellular carcinoma. Cancer Res. 2009;69.
33. Wu JM, Sheng HM, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu MG, Nakshatri H, and **Maluccio MA**. NF-kappa B inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Letters. 2009;278(2):145- 55.
34. Zook JE, Sandrasegaran K, Saxena R, Price T, **Maluccio M**, Kwo P, Johnstone P, Cardenes H. Orthotopic Liver Transplant (OLT) following Stereotactic Body Radiation Therapy (SBRT) in Patients with Hepatocellular Carcinoma (HCC): Radiologic and Pathologic Correlation. Int J Radiat Oncol. 2009;75(3):S285-S6.
35. Andolino DL, **Maluccio M**, Calley C, Kwo P, Tector AJ, Johnstone PAS, Cardenes

H. Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma (HCC): The Indiana University Experience. Int J Radiat Oncol. 2010;78(3):S74

1. Cardenes HR, Price TR, Perkins SM, **Maluccio M**, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PAS. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clinical & Translational Oncology. 2010;12(3):218-25.
2. **Maluccio M**, Lazar M. Involvement of Osteopontin in the Matrix-Degrading and Proangiogenic Changes Mediated by Nicotine in Pancreatic Cancer Cells Discussion. Journal of Gastrointestinal Surgery. 2010;14(10):1577.
3. Wu JM, Skill NJ, and **Maluccio MA**. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. Hpb. 2010;12(9):625-36.
4. Wu JM, Xu Y, Skill NJ, Sheng HM, Zhao ZW, Yu MG, Saxena R, and **Maluccio MA**. Autotaxin expression and its connection with the TNF-alpha-NF-kappa B axis in human hepatocellular carcinoma. Molecular Cancer. 2010;9. 10.1186/1476- 4598-9-71. PubMed.
5. Andolino DL, Johnson CS, **Maluccio M**, Kwo P, Tector AJ, Zook J, Johnstone PAS, Cardenes HR. Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma. Int J Radiat Oncol. 2011;81(4):E447-E53.
6. Klingler K, Mangus S, and **Maluccio M**. Pre-Liver Transplant Therapies for Hepatocellular Carcinoma Can Achieve Equivalent Survival for Patients with Worse Prognosis. J Invest Med. 2011;59(1):205-.
7. Skill NJ, Scott RE, Wu JM, and **Maluccio MA**. Hepatocellular Carcinoma Associated Lipid Metabolism Reprogramming. Journal of Surgical Research. 2011;169(1):51-6.
8. Skill NJ, Xu Y, Zhao ZW, Wu JM, and **Maluccio MA**. Lysophosphatidic Acid Variant Profiles in Hepatocellular Carcinoma. Hepatology. 2011;54:1398a.
9. Cardenes HR, Lasley FD, Kwo P, Perkins SM, and **Maluccio MA**. Stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma with Child-Pugh class B. J Clin Oncol. 2012;30(15). PubMed PMID: WOS:000318009803496.
10. Lasley FD, Calley C, Perkins SM, **Maluccio M**, Kwo P, Cardenes H. Phase I-II Trial of Stereotactic Body Radiation Therapy (SBRT) in Patients with Hepatocellular Carcinoma, Child-Pugh Class (CPC) A and B: Interim Analysis of Treatment Variables Affecting Toxicity and Outcome. Int J Radiat Oncol. 2012;84(3):S10-S.
11. **Maluccio M**, Covey A. Recent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma. Ca-Cancer J Clin. 2012;62(6):394-9.
12. Price TR, Perkins SM, Sandrasegaran K, Henderson MA, **Maluccio MA**, Zook JE, Tector AJ, Vianna RM, Johnstone PAS, Cardenes HR. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. 2012;118(12):3191-8.
13. Afolabi O, Mangus RS, **Maluccio MA**, Kubal CA, Fridell JA, Vianna RM, Bell J, Tector AJ. Utility of Screening Colonoscopy in Liver Transplant Patients. Am J Transplant. 2013;13:80-1.
14. Baniasadi H, Gowda GAN, Gu HW, Zeng A, Zhuang S, Skill N, **Maluccio M**, Raftery

D. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. Electrophoresis. 2013;34(19):2910-7.

1. Elnekave E, Erinjeri JP, Brown KT, Thornton RH, Petre EN, Maybody M, **Maluccio MA**, Hsu M, Sofocleous CT, Getrajdman GI, Brody LA, Solomon SB, Alago W, Fong Y, Jarnagin WR, Covey AM. Long-Term Outcomes Comparing Surgery to

Embolization-Ablation for Treatment of Solitary HCC < 7 cm. Annals of Surgical Oncology. 2013;20(9):2881-6.

1. Goodman B, Calley C, **Maluccio M**, Helft P, Chiorean E, Cardenes H. Survival Efficacy Following Stereotactic Body Radiation Therapy for Limited Liver Metastases. Int J Radiat Oncol. 2013;87(2):S190-S.
2. Goodman B, Johnson CS, Gebregziabher N, **Maluccio MA**, Helft PR, Chiorean EG, Cardenes HR. Stereotactic body radiotherapy response and local control rates for hepatic oligometastases. J Clin Oncol. 2013;31(15)..
3. Lasley FD, Johnson CS, Mannina EM, **Maluccio M**, Kwo P, Cardenes H. Relationship of Hepatic Toxicity to Advancement of Child-Pugh Score and Overall Survival for Patients Treated With SBRT to the. Liver. Int J Radiat Oncol. 2013;87(2):S27-S8.
4. Mannina EM, Lasley FD, Calley C, Saxena R, **Maluccio MA**, Tector AJ, Kwo PY, Cardenes HR. Role of Stereotactic Body Radiation Therapy as a Bridge to Orthotopic Liver Transplantation: Evaluation of Pathological Response and Outcome. Int J Radiat Oncol. 2013;87(2):S323-S4
5. Skill N, Wu JM, Xu Y, Zhao Z, and **Maluccio M**. Lysophosphatidic Acid Aberrancies and Hepatocellular Carcinoma: Studies in the MDR2 Gene Knockout Mouse. Cancer Investigation. 2013;31(2):145-55.
6. Skill NJ, Wu JM, Yan X, Zhao ZW, Tector AJ, and **Maluccio MA**. Lysophospholipid variants in hepatocellular carcinoma. Journal of Surgical Research. 2013;182(2):241-9.
7. Tiwari S, Mangus RS, **Maluccio MA**, Fridell JA, Kubal CA, Vianna RM, Tector J. Impact of Tobacco Use on Cancer Incidence in Liver Transplantation. Am J Transplant. 2013;13:92
8. Bowers J, Hughes E, Skill N, **Maluccio M**, Raftery D. Detection of hepatocellular carcinoma in hepatitis C patients: Biomarker discovery by LC-MS. J Chromatogr B. 2014;966:154-62.
9. Goodman B, Cardenes H, Helft P, **Maluccio M**. Safety and Efficacy of Stereotactic Body Radiation Therapy for Hepatic Oligometastases: Ten-Year Update. Int J Radiat Oncol. 2014;90:S375-S6.
10. Goodman B, Cardenes HR, **Maluccio MA**, Helft PR. Hepatic oligometastases treated with stereotactic body radiation therapy: Updated 10-year analysis of the Indiana University experience. J Clin Oncol. 2014;32(15).
11. Lasley FD, Kwo P, Althouse S, Perkins SM, **Maluccio MA**, Cardenes HR. Final results of a phase II trial of stereotactic body radiotherapy (SBRT) in patients with hepatocellular carcinoma (HCC) with Child-Pugh class A (CPC-A). J Clin Oncol. 2014;32(15).
12. Mangus RS, **Maluccio M**, Kubal CA, Fridell JA, Tector AJ. Multivisceral Transplantation for Non-Resectable Abdominal Neuroendocrine Tumors. Gastroenterology. 2014;146(5):S1031-S.
13. Mannina EM, Lasley FD, Saxena R, **Maluccio M**, Tector J, Kwo P, Cardenes H. Radiologic Versus Pathologic Assessment of Response in Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol. 2014;90:S379-S80.
14. Marrero J, **Maluccio MA**, McCurdy H, Abou-Alfa GK. Expert Perspectives on Evidence-Based Treatment Planning for Patients With Hepatocellular Carcinoma. Cancer Control. 2014;21(2):5-16.
15. Bhat M, Skill N, Marcus V, Deschenes M, Tan XM, Bouteaud J, Negi S, Awan Z, Aikin R, Kwan J, Amre R, Tabaries S, Hassanain M, Seidah NG, **Maluccio M**, Siegel P, Metrakos P. Decreased PCSK9 expression in human hepatocellular carcinoma. Bmc Gastroenterology. 2015;15.
16. Lasley FD, Mannina EM, Johnson CS, Perkins SM, Althouse S, **Maluccio M**, Kwo P, Cardenes H. Treatment variables related to liver toxicity in patients with hepatocellular carcinoma, Child-Pugh class A and B enrolled in a phase 1-2 trial of stereotactic body radiation therapy. Practical Radiation Oncology. 2015;5(5):E443- E9.
17. Mannina EM, Perkins S, Sandra A, Lasley FD, **Maluccio M**, Cardenes HR. Results of a Phase 2 trial of Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma. Int J Radiat Oncol. 2015;93(3):S112-S3.
18. Nagai S, Mangus RS, Frost E, Kubal CA, Ekser B, Fridell JA, Kwo P, **Maluccio MA**, Tector AJ. Predictors for Outcome of Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Successful Treatment and Long Survival. Transplantation. 2015;99:225-
19. Nagai S, Mangus RS, Kubal CA, Ekser B, Fridell JA, Klingler KR, **Maluccio MA**, Tector AJ. Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival. Clinical Transplantation. 2015;29(12):1156-63.
20. Territo PR, **Maluccio M**, Riley AA, McCarthy BP, Fletcher J, Tann M, Saxena R, Skill NJ. Evaluation of C-11-Acetate and F-18-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. Bmc Medical Imaging. 2015;15.
21. Theodorakis N, **Maluccio M**, Skill N. Murine study of portal hypertension associated endothelin-1 hypo-response. World J Gastroentero. 2015;21(16):4817-28.
22. Goodman BD, Mannina EM, Althouse SK, **Maluccio MA**, Cardenes HR. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Practical Radiation Oncology. 2016;6(2):86-95.
23. Milgrom DP, **Maluccio MA**, Koniaris LG. Management of Hepatocellular Carcinoma (HCC). Curr Surg Rep. 2016;4(6). 10.1007/s40137-016-0143-4. PubMed PMID: WOS:000406549700003.
24. Dakhoul L, Ghabril M, Mcshane C, Jones K, Vuppalanchi R, Samala N, **Maluccio MA,** Gawrieh S, Chalasani NP, Nephew LD. Characteristics and Outcomes of Hepatocellular Carcinoma (HCC) differ in Black versus White patients: a 15-Year Large Transplant Center Experience. Hepatology. 2017;66:327a-8a..
25. Dakhoul L, Mcshane C, Jones K, Ghabril M, Vuppalanchi R, Samala N, Vilar- Gomez **E, Maluccio MA**, Chalasani NP, Gawrieh S. Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease. Hepatology. 2017;66:1118a.
26. Kong FM, Zang Y, Pi WH, Long D, Ellsworth S, Saito N, Ghabril M, Lacerda MA, Agarwal DM, O'Neil B, Tann M, Zellars RC, and **Maluccio MA**. Stereotactic body radiation therapy to generate comparable survival to surgery in treating hepatocellular carcinoma (HCC): Results of 756 patients. J Clin Oncol. 2017;35.
27. **Maluccio MA**, Zang Y, Pi WH, Tann M, Kubal C, Lacerda MA, O'Neil BH, Agarwal DM, Kong FM. Survival in patients with hepatocellular carcinoma (HCC): A report of 1444 patients treated within a multidisciplinary program. J Clin Oncol. 2017;35.
28. Mangus R, Graham R, and **Maluccio M**. Post Liver Transplant Cancer Risk in Patients Receiving Antibody-Based Immunosuppression Induction. Annals of Surgical Oncology. 2017;24:S164-S..
29. Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, Cox JA, Saxena R, Tector J, and **Maluccio M**. Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes. Int J Radiat Oncol. 2017;97(5):931-8.
30. Pi W, Zang Y, Zhang H, Yao H, Ellsworth S, Long D, Wang W, Jin JY, Zellars RC, **Maluccio M**, Kong FM. Factors Associated With Overall Survival After Radiation Therapy in Patients With Hepatocellular Carcinoma. Int J Radiat Oncol. 2017;99(2):E179-E.
31. Skill NJ and **Maluccio MA**. Lysophosphatidic acid receptor signaling and pancreatic adenocarcinoma tumor microenvironment. Cancer Res. 2017;77.
32. Bush WJ, Davis JP, **Maluccio MA**, Kubal CA, Salisbury JB, Mangus RS. Computed Tomography Measures of Nutrition in Patients With End-Stage Liver Disease Provide a Novel Approach to Characterize Deficits. Transpl P. 2018;50(10):3501-7.
33. Butler J, Skill N, Kubal C, O'Brien D, Kays J, Fridell J, and **Maluccio M**. Financial Burden of Liver Transplant vs Resection for HCC. Am J Transplant. 2018;18:456- 7.
34. Hinton J, Galle JO, Long D, Deig C, Kong FM, **Maluccio M**, Shahda S, O'Neil BH, Ellsworth SG. Long-Term Survival and Local Control Outcomes in Oligometastatic Colorectal Cancer Treated with Liver Stereotactic Body Radiation Therapy Long-

Term Survival and Local Control Outcomes in Oligometastatic Colorectal Cancer. Int J Radiat Oncol. 2018;102(3):E6-E.

1. Long D, Huang K, Tann M, Galle JO, Rosetta JL, Bartlett GK, **Maluccio M**, Rhome RM, Kong FM. Functional Liver Image-Guided Hepatic Therapy (FLIGHT) with Hepatobiliary Iminodiacetic Acid (HIDA) Scans: Predictors of Functional Dosimetric Improvements. Int J Radiat Oncol. 2018;102(3):S6-S7.
2. Long D, Tann M, Huang K, Bartlett GK, Galle JO, Furukawa Y, **Maluccio M**, Cox JA, Kong FM. Functional Liver Image-Guided Hepatic Therapy (FLIGHT) with Hepatobiliary Iminodiacetic Acid (HIDA) Scans: Functional Parameters May Predict for Decompensation after Stereotactic Body Radiation Therapy (SBRT). Int J Radiat Oncol. 2018;102(3):E59-E.
3. Milgrom D, Valsangkar N, Kays J, Liang T, Butler J, Kubal C, **Maluccio M**, Tector A, Koniaris L. Advanced Liver Care and Salvage Transplantation Improves Outcomes for Patients with Cirrhosis Requiring Abdominal General Surgical Procedures. Am J Transplant. 2018;18:724-..
4. Arbab M, **Maluccio M**, Kong M, Ellsworth SG, Rhome RM. Predictors of Failure and Survival in Patients with Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy. Int J Radiat Oncol. 2019;105(1):E212-E3
5. Hinton J, Agrawal N, Rhome RM, Long D, Galle JO, Burney H, O'Neil BH, Zang Y, **Maluccio M**, Shahda S, Ellsworth SG. Long-Term Survival and Local Control Outcomes in Oligometastatic Colorectal Cancer Treated with Liver Stereotactic Body Radiation Therapy. Int J Radiat Oncol. 2019;105(1):E566-E7.
6. Lattimore SG, Skill NJ, Tann M, and **Maluccio MA.** Pilot Study to Evaluate Prognostic and Predictive Markers of Peptide Receptor Radionucleotide Therapy Response in Neuroendocrine Tumor Patients. J Am Coll Surgeons. 2019;229(4):E103-E4.
7. Long DE, Huang C, Tann M, Dawson B, Bartlett G, **Maluccio MA**, Rhome R, Kong FMS, Ellsworth SG. Prospective trial of functional liver image-guided hepatic therapy (FLIGHT) with hepatobiliary iminodiacetic acid (HIDA) scans and update of institutional experience. J Clin Oncol. 2019;37(4).
8. Ries S, Skill NJ, Campbell E, Daniel R, Kubal CA, Richard MS, and **Maluccio MA**. Metabolomic Study Of Sarcopenia In Patients Prior To Liver Transplantation. Am J Transplant. 2019;19:760-.
9. Skill N and **Maluccio M**. Contemporary paradigm for the evaluation and treatment of hereditary gastric cancer. Transl Gastroent Hep. 2019;4.
10. Skill NJ, Butler J, O’Brien DC, Kays JK, Kubal CA, Liangpunsakul S, Ninad N, and **Maluccio MA**. Financial Burden of Liver Transplant vs Resection for Hepatocellular Carcinoma. Trans Proc 2019:51(6):1907
11. Kays JK, Milgrom DP, Butler JR, Liang TW, Valsangkar NP, Wojcik B, Frye CC,

**Maluccio MA**, Kubal CA and Koniaris LG. Specialized care improves outcomes for

patients with cirrhosis who require general surgical operations. PLoS One. 2019;14(10)

1. Skill NJ, Elliott CM, Ceballos B, Saxena R, Pepin R, Bettcher L, Ellensberg M, Raftery D, **Maluccio MA**, Ekser B, Mangus RS, Kubal CA. Metabolomic Characterization of Human Model of Liver Rejection Identifies Aberrancies Linked to Cyclooxygenase (COX) and Nitric Oxide Synthase (NOS). Ann Transpl. 2019;24:341-9.
2. Skill N, Campbell E, Milosavljevic T, Chouest E, Voros B, Woltering E, and **Maluccio M**. Liquid Biopsy Metabolomic Profiling of Neuroendocrine Cancer Patients. Pancreas. 2020;49(3):487-.
3. Ramirez R, Bren-Mattison Y, Ramcharan T, Boudreaux JP, Marsala A, Ryan P, and **Maluccio MA**. A Neuroendocrine Tumor Specialty Center in New Orleans’ (NOLANETS) Response to Patient Care During the Covid 19 Pandemic. Oncologist 2020;25(7):548
4. Landry J, Bren-Mattison Y, Ramirez R, Boudreaux JP, Woltering EA, **Maluccio MA,** and Ramcharan T. Management of Appendiceal Neuroendocrine Tumors: Beyond Tumor Size. J of Cancer Immunology. 2020.
5. Fa A, Danos D, Maniscalco L, Yi Y, Wu XC, Maluccio MA, Chu C, and Lyons J. Is there really a difference in outcomes between men and women with hepatocellular cancer? Cancers 2023

## Book Chapters:

Maluccio, M Handbook of Hepato-Pancreato-Biliary Surgery – Primary Liver Cancer (Hepatocellular Carcinoma) and Cholangiocarcinoma Lippincott Williams & Wilkin s, Sep 9, 2015 pages 58-62

## Videos, Electronic Media, and Multimedia Interviews:

National Public Radio Interview Trends in Treatment of HCC 2012

Reach MD 2012

Cancer Control - Trends in the treatment of cholangiocarcinoma 2013

Cure Magazine - Contemporary Management of Hepatocellular Carcinoma 2014 Carcinoid Cancer Foundation 2020

Facebook live - multidisciplinary cancer care 2020

Facebook live – Boudreaux - surgical management of NET 2020

Facebook live – Ryan Griffin – chemotherapy and clinical trials 2021

Facebook live – Tracie Weil-Cavalier – NET and nutritional 2021

Facebook live – Dan Lee – PRRT 2021

Facebook live – Andrew Marsala Liver directed therapies in NET 2021

Carcinoid Cancer Foundation 1/2022

NETRF 2022

NCAN – get real podcast- Clinical Trials 2022

WVUE New Rare Cancer Program at LCMC 8/2022

Carcinoid Cancer Foundation 8/2022

WVUE update on clinical trials in neuroendocrine 12/2022

Carcinoid Cancer Foundation 7/2023

|  |  |
| --- | --- |
|  |  |

**Research Review Committee:**

NIH Scientific Review Committee Member 2006, 2012, 2019, 2022: Specialist panel to review program project grants on biomarker discovery related to primary liver cancer.

NIH Scientific Review Committee Member–Spore Grant Review 2020, 2022, 2023: Specialist panel to review Spore grants related to GI and neuroendocrine cancers.

NIH Scientific Review Committee 2021: Special Emphasis – Biomarkers in Cancer

NIH Scientific Review Committee 2021, 2022: P50 application targeting disparities in cancer treatment

NIH Scientific Review Committee 2021, 2022: Spore Grants targeting rare cancers

NIH Scientific Review Committee 2022: Technologies for Global Health, Special Emphasis Panel (J1)

NIH Scientific Review Committee 4/2022, 10/1022, 2/2023: Subspecialty Spore Spore Grants (P50)

## Select Invited Presentations and Seminars:

* 1. IU Cancer Center Grand Rounds

Treatment modalities for primary liver cancer 2005

* 1. GI Grand Rounds 2005

Hepatocellular Carcinoma: Expectations of the available treatment options

* 1. GI Regional Symposium

Metastatic Colorectal Cancer - resection and ablation, 2005

* 1. Columbus Regional Grand Rounds Management of Hepatocellular Carcinoma, 2006
  2. Society of Surgical Oncology

The Stellate Cell in Hepatocellular Carcinoma, 2006

* 1. Cancer Center Grand Rounds

Regional Therapies for hepatocellular Carcinoma, 2006

* 1. GI Regional Symposium

Hepatocellular Carcinoma Resection and Ablation, 2006

* 1. Annual Cancer Symposium to emphasize diagnostic, therapeutic advances HCC, 2006
  2. St Joseph’s Medical Center Grand Rounds Primary and Metastatic Liver Cancer, 2007
  3. Memorial Hospital Grand Rounds

Multidisciplinary management of Liver Cancer, 2007

* 1. GI Regional Symposium

Metastatic Colorectal Cancer - resection/infusion/ablation, 2007

* 1. St Joe’s Hospital System

Multidisciplinary Management of Liver Cancer, 2 00 8

* 1. Clinical Outreach

Cancer treatment in the context of transplantation, 2008

* 1. Clinical Oncology Congress -San Francisco

Interdisciplinary management of primary and metastatic tumors of the liver, 2008

* 1. Surgical Grand Rounds

Evolution of the IU Liver Oncology Program, 2009

* 1. Reed Hospital Grand Rounds

Multidisciplinary model for the care of liver cancer patients, 2009

* 1. Miami Symposium

Multidisciplinary approach to the treatment of liver malignancies, 2009

* 1. Clinical Outreach

Cancer outcomes after transplantation for HCC, 2010

* 1. Annual McGill University Hepatopancreaticobiliary and Liver Transplant Symposium

Management of Hepatocellular Carcinoma in the context of Liver Transplantation 2010

* 1. Society of Interventional Radiology National Symposium on Yttrium 90 Scottsdale AZ

Y90 Patient Selection and Outcomes - metastatic disease, 2011

* 1. Goshen Health System

Statewide Cancer Program Development, 2011

* 1. Methodist Hospital Grand Rounds

Role of the multidisciplinary clinic in the treatment of liver cancer patients 2013

* 1. Clinical Outreach

Putting neuroendocrine treatment into perspective, 2013

* 1. Cancer Survivorship Symposium, 2012, 2013
  2. Cancer Support Community Multidisciplinary cancer care, 2014
  3. Cancer Support Community

Somatostatin receptor imaging in neuroendocrine tumors, 2014

* 1. IU Health Arnett Outreach Seminar

Current algorithms for the management of HCC, 2014

* 1. National Association for Neuroendocrine Tumors (NANETS) Ga68 imaging in metastatic neuroendocrine patients, 2014
  2. Surgical Grand Rounds

Surgical Management of Metastatic Colorectal Cancer, 2015

* 1. Schneck Medical Center Grand Rounds

Multimodality treatment of neuroendocrine tumors, 2015

* 1. Jay County Hospital System

Current algorithms for the management of primary and secondary liver tumors 2015

* 1. Ball Memorial Grand Rounds

Multidisciplinary approach to liver malignancies, 2015

* 1. Cancer Support Community

Multivisceral transplantation for neuroendocrine, 2015

* 1. Miami International Symposium Miami Transplant Institute Contemporary HCC management strategies, 2015
  2. Surgical Grand Rounds

Evolving Treatment Paradigms for Neuroendocrine Malignancies - The development of programmatic infrastructure at Indiana University, 2016

* 1. Research Faculty Presentation

Liver Oncology Research Program, 2016

* 1. Outreach Seminar – neuroendocrine patient support groups Surgical management of primary and metastatic NET, 2017
  2. Regional Neuroendocrine Symposium – Indianapolis The multimodality management of NET, 2017
  3. LSU Department of Surgery Grand Rounds Programmatic Development as a Professional Niche-

Making a case for MVOT in metastatic neuroendocrine tumors, 2018

* 1. Tulane University Surgery Grand Rounds Programmatic Development as a Professional Niche-

Making a case for a multi-institutional, multistate NET program in the Southern Region, 2019

* 1. LSU Department of Surgery Grand Rounds Programmatic Development as Professional Niche-

Critical infrastructure for a cost-effective liver oncology program, 2021

* 1. Our Lady of the Lake Surgery Invited Lectureship Programmatic Development as a Professional Niche-

Making the case for a Rare Cancer Program in the Southern Region, 2022

* 1. NCAN regional patient advocacy conference Charlotte NC- Surgical management of midgut and bronchopulmonary neuroendocrine tumors 2022
  2. LSU Department of Surgery Grand Rounds. Our Exodus from Kenner Hospital and Making a case for a multisite rare cancer program in the South, 2022
  3. NCAN national patient advocacy conference Atlanta GA – Surgical management of primary and metastatic midgut neuroendocrine tumors 10/2022
  4. NCAN regional patient advocacy conference Silver Springs MD – surgical management of pancreatic neuroendocrine tumors. 2/2023
  5. CAGLA Neaux Cancer Conference – session panelist for the GI oncology case presentations 3/2023
  6. NCAN regional patient advocacy conference Omaha NE – conference moderator on the multidisciplinary management of neuroendocrine tumors and neuroendocrine carcinomas 4/2023

## Editorial Posts and Activities

**Journal Editor or Associate Editor:**

International Journal of Physiology, Pathophysiology and 2004 – 2008

Pharmacology

## Reviewer:

Hepatology 2008 –present

The British Journal of Surgery, 2009 –present

The World Journal of Gastroenterology. 2009 –present The International Journal of Gastrointestinal Surgery. 2009 - present International Journal of Cancer 2008 - present

International Journal of Gastroenterology 2010 - present

Cancer Control Journal Reviewer 2016 – present

Transplantation 2018 – present

Clinical Transplantation 2018-present

# SERVICE ACTIVITIES

## University/Institutional Service Departmental committees:

Indiana University

|  |  |
| --- | --- |
| Resident Review Committee | 2003 - 2019 |
| Transplant Committee Oncology Representative | 2011 - 2019 |
| IUHP Human Resources Committee | 2015 - 2018 |
| Surgery Research Committee | 2016 - 2019 |
| Diversity in Surgery Committee | 2016 - 2019 |
| Surgery Promotion and Tenure Committee | 2017 - 2019 |

LSUHSC

Promotion and Tenure Committee 2020-3/2023

Resident Review Committee 2020 - present

## School committees:

|  |  |
| --- | --- |
| Indiana University |  |
| Cancer Center Institutional Review Board (IRB) | 2006 - 2019 |
| IU Simon Cancer Center Scientific Review Committee | 2008 - 2018 |
| IU Simon Cancer Center Commission on Cancer Committee | 2012 – 2018 |
| IU Simon Cancer Center  Bio-repository Tissue Acquisition committee | 2012-2019 |

IU Simon Cancer Center

Comprehensive Cancer Center Steering Committee 2016 – 2019

Institutional Animal Care and Use Committee (IACUC) 2016 - 2019

## Campus committees:

Indiana University Purdue University Indianapolis Campus

Women in Medicine Committee 2010 – 2018

Human Resources Medical School Steering Committee 2015 – 2018

LSUHSC

Tulane Endocrine Surgery Fellowship, Faculty 2020 - present

Research Grant Review Committee 2021 - present

LSU Endocrinology Fellowship, Faculty 2021 - present

## Hospital committees:

Indiana University Hospital

Transplant Committee 2011 – 2019

Simon Cancer Center executive committee 2017 – 2019

UNOS advisory board 2012 - 2016

## National Service:

United Network for Organ Sharing Consensus Panel Member 2010 - 2012

Established the guidelines for consideration of transplant in the setting of cancers transplantation in the setting of cancer

Cancer Advisory Board 2010 - 2017

*I have participated with members from cancer centers around the country evaluating the impact of changes within the health care delivery system on cancer care and how to navigate while maintaining optimal clinical outcomes.*

American Board of Surgery Board Examiner 2014 (active) Invited faculty representing the Mid-West Region for the general surgery oral board examinations for ABS certification.

American Board of Surgery Complex Surgical Oncology 2014 (active) Board Member Solo LSU faculty member and one of only 2 women surgical oncologists representing the Southern Region for the surgical oncology sub- specialty board examinations.

## Clinical Service:

Former director of liver oncology at Indiana University/IU Health System 2006- 2019

High volume surgical oncology practice. Specialize in Hepato-Pancreatico-Biliary and Rare cancers. 2019-present

Current director of LSUHSC neuroendocrine cancer program NOLANETS 2019 – present

Chief of surgical oncology. 2020-present

Current director of the LSUHSC/LCMC Rare Cancer Program at East Jefferson Hospital 5/2022-present

## In-patient service activities:

2009 - 2019 Indiana University Hospital

>45 weeks/yr. Average 4hrs/day.

2019 – 5/2022 Ochsner Kenner Medical Center

>45 weeks/yr. Average >4hrs/day.

5/2022-present East Jefferson Hospital/LCMC

>45 weeks/yr. Average > 3hrs/day

## Clinic coverage:

2005 - 2019 Indiana University Hospital

3 clinic days/week. Average > 8 hrs/clinic day

2010 – 6/2019 Liver oncology multidisciplinary clinic, Wednesdays > 9hrs/clinic day

7/2019-5/2022 Neuroendocrine Subspecialty Clinic – Kenner Hospital 4 clinic days/week. Average >8 hrs/clinic day

1600 patient encounters/year

6/2022-present East Jefferson Oncology Clinic – Neuroendocrine and Rare Cancer Program

3 clinic days/week, average > 9rs/clinic day

## Call:

2009 - 2019 Indiana University Hospital – General Surgery Call

>30d/year.

2019 – present LSUHSC Neuroendocrine Cancer Call >120d/yr.

## Administrative Responsibilities

### Departmental:

2011 - 2019

Indiana University. Director Liver Oncology Program. To expand and improve quality and access to treatment for liver cancer. Build multidiscipline clinic for patients. Conduct and support clinical and basic research focused on etiology, stratification and novel treatments of liver cancer.

2016 – 2020

Indiana University. Director Indiana University Transplant Immunology (TRIM) CAP/CLIA Laboratory. Oversee CAP accredited and CLIA compliant clinical testing laboratory and personal. Ensuring compliance with Indiana State and Federal CMS regulations. Certifying results for clinical accuracy.

2019 – present

LSUHSC. Director of Neuroendocrine Cancer Program. To expand and improve quality and access to treatment for neuroendocrine cancer. Maintain and expand access to treatment. Conduct and support clinical and basic research focused on etiology, stratification and novel treatments of neuroendocrine cancer. Liaise with medical partners to provide sufficient and reliable resources.

2020 – 3/2023

LSUHSC Head Department of Surgery Promotion and Tenure. Review and certify applications for promotion and tenure from the department of surgery.

2020 – present

LSUHSC. Chief Division of Surgical Oncology. Oversee surgical oncology programs. Strategize for the expansion and efficiency of division to maximize impact and encourage professional growth for the surgical oncology faculty.

## Community Service Activities:

College Park Christian Church 2016 Outreach Community food bank

College Park Christian Church 2017 Outreach Brookside Community Development Project

College Park Christian Church 2018 Outreach Clothes Drive

PANCAN walk for the cure 2022 Cancer Fundraiser New Orleans Ribbons Rock the Runway 10/2022 Cancer Fundraiser New Orleans